Back to Search
SARENA HAYER, MD
MD
Obstetrics & Gynecology Physician
NPI: 1457937245Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Obstetrics & Gynecology PhysicianPrimary
Obstetrics & Gynecology
Code: 207V00000X
A201341(CA)
Research & Publications (20)
B-cell infiltrates induce endosteal bone formation in inflammatory arthritis.
PMID 18505368·J Bone Miner Res·2008
7-preclinical
Differentially regulated expression of growth differentiation factor 5 and bone morphogenetic protein 7 in articular cartilage and synovium in murine chronic arthritis: potential importance for cartilage breakdown and synovial hypertrophy.
PMID 18163510·Arthritis Rheum·2008
7-preclinical
Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis.
PMID 17195210·Arthritis Rheum·2007
7-preclinical
Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
PMID 16447221·Arthritis Rheum·2006
7-preclinical
Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo.
PMID 16207331·Arthritis Res Ther·2005
4-observational
JNK1 is not essential for TNF-mediated joint disease.
PMID 15642137·Arthritis Res Ther·2005
7-preclinical
Mechanisms of Disease: the link between RANKL and arthritic bone disease.
PMID 16932627·Nat Clin Pract Rheumatol·2005
6-review
Aberrant expression of the autoantigen heterogeneous nuclear ribonucleoprotein-A2 (RA33) and spontaneous formation of rheumatoid arthritis-associated anti-RA33 autoantibodies in TNF-alpha transgenic mice.
PMID 16339574·J Immunol·2005
7-preclinical
Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption.
PMID 16234431·FASEB J·2005
7-preclinical
Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation.
PMID 15125796·J Bone Miner Res·2004
7-preclinical
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
PMID 15248234·Arthritis Rheum·2004
7-preclinical
Overexpression of tumor necrosis factor causes bilateral sacroiliitis.
PMID 15022345·Arthritis Rheum·2004
7-preclinical
Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis.
PMID 14742260·Am J Pathol·2004
4-observational
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
PMID 14730626·Arthritis Rheum·2004
7-preclinical
Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
PMID 14673982·Arthritis Rheum·2003
6-review
Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
PMID 12847699·Arthritis Rheum·2003
7-preclinical
Osteoclasts are essential for TNF-alpha-mediated joint destruction.
PMID 12438440·J Clin Invest·2002
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3181 SW SAM JACKSON PARK RD, OHSU
PORTLAND, OR 97239 - Phone
- (503) 494-8211
Quick Facts
- NPI
- 1457937245
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile